UPDATE: UBS Upgrades Seattle Genetics
In a research note released Wednesday, UBS analyst Matthew Roden upgraded Seattle Genetics (NASDAQ: SGEN) from Neutral to Buy and maintained a $48.00 price target.
Roden said the firm made the upgrade based on two primary reasons: the stock's underperformance this year due to increased speculation in regards to the phase-3 data expected; and, that the analyst believes that the proprietary pipeline development is not reflected in the stock.
Roden continued to say that fear over AETHERA may be overstated and ultimately believes that upside will be driven by the pipeline.
Latest Ratings for SGEN
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | JMP Securities | Maintains | Market Outperform | |
| Feb 2022 | Morgan Stanley | Maintains | Overweight | |
| Feb 2022 | HC Wainwright & Co. | Maintains | Buy |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Matthew Roden UBSAnalyst Color Upgrades Price Target Analyst Ratings
